Welcome to the future of personal diagnostics.

Welcome to the future of personal diagnostics.

Illustrative prototype – Copyright: Digital Diagnostics AG

Illustrative prototype – Copyright: Digital Diagnostics AG

digid is developing a breakthrough digital diagnostics platform built upon its proprietary nanotech CantisenseTM biosensor technology and an ecosystem of mobile applications to enable real-time, A.I-powered diagnostics of human and animal biodata.

Mission

Our mission is to bring the power of a laboratory to everyone’s smartphone.

digid is developing a breakthrough digital diagnostics platform built upon its proprietary nanotech CantisenseTM biosensor technology and an ecosystem of mobile applications to enable real-time, A.I-powered diagnostics of human and animal biodata.

Mission

Our mission is to bring the power of a laboratory to everyone’s smartphone.

Product

digid Cantisense™ SARS-CoV-2-Test

Based on digid´s proprietary Cantisense™ technology, we have developed the world’s first SARS-CoV-2 antigen point-of-care (PoC) test.

The “digid Cantisense™ SARS-Cov-2 Test“ is a novel point-of-care test kit for professional usage, allowing to determine within minutes whether a person is infected with the SARS-CoV-2 virus.

Illustrative prototype – Copyright: Digital Diagnostics AG

Product

digid Cantisense™ SARS-CoV-2-Test

Based on digid´s proprietary Cantisense™ technology, we have developed the world’s first SARS-CoV-2 antigen point-of-care (PoC) test.

The “digid Cantisense™ SARS-Cov-2 Test“ is a novel point-of-care test kit for professional usage, allowing to determine within minutes whether a person is infected with the SARS-CoV-2 virus.

Illustrative prototype – Copyright: Digital Diagnostics AG

Direct detection of the SARS CoV-2 virus in the patient sample
Test result available within a few minutes
A.I.-powered data analytics and diagnostics platform
A scalable digital ecosystem with mobile applications for professional users
Direct detection of the SARS CoV-2 virus in the patient sample
A.I.-powered data analytics and diagnostics platform
Test result available within a few minutes
A scalable digital ecosystem with mobile applications for professional users

Leveraging digid´s groundbreaking technology to fight Covid-19.

Digital Diagnostics AG has established a consortium of experts from various fields, such as the renowned Helmholtz Center for Infection Research (HZI) and highly specialized medical device manufacturing companies to develop and produce the “digid Cantisense™ SARS-Cov-2 Test” at scale to enable faster testing for the SARS-CoV-2 virus. The aim is to enable faster and more precise detection of the SARS-CoV-2 virus.

Leveraging digid´s groundbreaking technology to fight Covid-19.

Digital Diagnostics AG has established a consortium of experts from various fields, such as the renowned Helmholtz Center for Infection Research (HZI) and highly specialized medical device manufacturing companies to develop and produce the “digid Cantisense™ SARS-Cov-2 Test” at scale to enable faster testing for the SARS-CoV-2 virus.
The aim is to enable faster and more precise detection of the SARS-CoV-2 virus.

.01

Supporting the detection of SARS CoV-2 virus spread within specific geographies

.02

Enables governments and communities to design highly targeted counter measures
.03
Provides a fast and reliable testing option for sensitive or public infrastructure such as hospitals, homes for the elderly, venues, schools or airports.

.01

Supporting the detection of SARS CoV-2 virus spread within specific geographies

.02

Enables governments and communities to design highly targeted counter measures
.03
Provides a fast and reliable testing option for sensitive or public infrastructure such as hospitals, homes for the elderly, venues, schools or airports.

Technology

Applying innovative technologies to digitalize diagnostics from the ground up.

.01

digid is developing a new kind of diagnostics platform by combining our proprietary nanotech CantisenseTM biosensor technology and an ecosystem of mobile applications to enable real-time A.I-powered diagnostics of human and animal biodata.

.02

At the very core of digid´s platform is our proprietary CantisenseTM biosensor technology, built upon the latest innovations in the field of nanotech and microelectromechanical systems (MEMS).

.03

Our real-time diagnostics solution enables the identification of human and animal biomarkers in real-time.

Technology

Applying innovative technologies to digitalize diagnostics from the ground up.

.01

digid is developing a new kind of diagnostics platform by combining our proprietary nanotech CantisenseTM biosensor technology and an ecosystem of mobile applications to enable real-time A.I-powered diagnostics of human and animal biodata.

.02

At the very core of digid´s platform is our proprietary CantisenseTM biosensor technology, built upon the latest innovations in the field of nanotech and microelectromechanical systems (MEMS).

.03

Our real-time diagnostics solution enables the identification of human and animal biomarkers in real-time.

Partners

Team

Constantin von Gersdorff

Constantin von Gersdorff

CEO

Dr. Frank Flacke

Dr. Frank Flacke

COO

Dr. Konstantin Kloppstech

Dr. Konstantin Kloppstech

CTO

Press

New 5 minute corona virus test delivers clear results on infection

Apr 6, 2020

A consortium of scientists and companies is developing a new 5 minute test for the SARS corona virus. In comparison to currently available rapid tests, the SARS-CoV-2 MEMS 5 Minute Test™ directly detects the virus over the entire course of the infection and can be...

Contact

Digital Diagnostics AG
Robert-Koch-Straße 30A
55129 Mainz
E-mail: info@digid.com

Press Inquiry

Thomas Huber // Semanticom GmbH
E: press@digid.com
T: +49 30 27580 81 11
|
|

©2020 Digital Diagnostics AG

Impressum // Data Policy // Disclamer